STOCK TITAN

Blueprint Medicines to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Blueprint Medicines (NASDAQ: BPMC) has announced its participation in two upcoming virtual investor conferences. The company will present at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET, and at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

Investors and interested parties can access live webcasts of both presentations through the Investors & Media section of Blueprint Medicines' website. Replays of the webcasts will be available on the company's website for 30 days following each presentation, providing an opportunity for those unable to attend the live events to catch up on the information shared.

Blueprint Medicines (NASDAQ: BPMC) ha annunciato la sua partecipazione a due prossime conferenze virtuali per investitori. L'azienda presenterà al Stifel 2024 Immunology and Inflammation Virtual Summit martedì 17 settembre 2024, alle 14:00 ET, e al TD Cowen's Chronic Urticaria Summit venerdì 20 settembre 2024, alle 11:00 ET.

Gli investitori e le parti interessate possono accedere alle dirette delle presentazioni attraverso la sezione Investitori & Media del sito web di Blueprint Medicines. Le registrazioni delle dirette saranno disponibili sul sito dell'azienda per 30 giorni dopo ciascuna presentazione, offrendo a coloro che non possono partecipare agli eventi dal vivo l'opportunità di recuperare le informazioni condivise.

Blueprint Medicines (NASDAQ: BPMC) ha anunciado su participación en dos próximas conferencias virtuales para inversores. La empresa presentará en el Stifel 2024 Immunology and Inflammation Virtual Summit el martes 17 de septiembre de 2024 a las 2:00 p.m. ET, y en el TD Cowen's Chronic Urticaria Summit el viernes 20 de septiembre de 2024 a las 11:00 a.m. ET.

Los inversores y partes interesadas pueden acceder a las transmisiones en vivo de ambas presentaciones a través de la sección de Inversores y Medios del sitio web de Blueprint Medicines. Las repeticiones de las transmisiones estarán disponibles en el sitio web de la empresa durante 30 días después de cada presentación, proporcionando una oportunidad para que aquellos que no puedan asistir a los eventos en vivo se pongan al día con la información compartida.

Blueprint Medicines (NASDAQ: BPMC)는 두 가지 예정된 가상 투자자 회의에 참가한다고 발표했습니다. 회사는 2024년 9월 17일 화요일 오후 2시 ET에 Stifel 2024 면역학 및 염증 가상 정상 회의에서 발표하고, 2024년 9월 20일 금요일 오전 11시 ET에 TD Cowen의 만성 두드러기 정상 회의에서 발표할 예정입니다.

투자자와 관심 있는 분들은 Blueprint Medicines 웹사이트의 투자자 및 미디어 섹션을 통해 두 발표의 라이브 웹캐스트를 확인할 수 있습니다. 각 발표 후 30일 동안 회사 웹사이트에서 웹캐스트의 재방송이 제공되어, 라이브 이벤트에 참석할 수 없는 분들이 공유된 정보를 따라잡을 수 있는 기회를 제공합니다.

Blueprint Medicines (NASDAQ: BPMC) a annoncé sa participation à deux prochaines conférences virtuelles pour investisseurs. L'entreprise présentera lors du Stifel 2024 Immunology and Inflammation Virtual Summit le mardi 17 septembre 2024 à 14 h ET, et au TD Cowen's Chronic Urticaria Summit le vendredi 20 septembre 2024 à 11 h ET.

Les investisseurs et les parties intéressées peuvent accéder aux diffusions en direct des deux présentations via la section Investisseurs & Médias du site web de Blueprint Medicines. Les rediffusions des diffusions seront disponibles sur le site de l'entreprise pendant 30 jours suivant chaque présentation, offrant ainsi aux personnes qui n'ont pas pu assister aux événements en direct la possibilité de rattraper les informations partagées.

Blueprint Medicines (NASDAQ: BPMC) hat seine Teilnahme an zwei bevorstehenden virtuellen Investorenkonferenzen angekündigt. Das Unternehmen wird am Dienstag, den 17. September 2024, um 14:00 Uhr ET beim Stifel 2024 Immunology and Inflammation Virtual Summit und am Freitag, den 20. September 2024, um 11:00 Uhr ET beim TD Cowen's Chronic Urticaria Summit präsentieren.

Investoren und Interessierte können die Live-Webcasts beider Präsentationen über den Bereich Investoren & Medien auf der Website von Blueprint Medicines abrufen. Die Aufzeichnungen der Webcasts werden 30 Tage nach jeder Präsentation auf der Website des Unternehmens verfügbar sein, sodass diejenigen, die an den Live-Veranstaltungen nicht teilnehmen konnten, die Möglichkeit haben, die geteilten Informationen nachzuholen.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences:

  • Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.
  • TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-302232128.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines (BPMC) presenting at the Stifel 2024 Immunology and Inflammation Virtual Summit?

Blueprint Medicines (BPMC) is presenting at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.

What time is Blueprint Medicines (BPMC) presenting at TD Cowen's Chronic Urticaria Summit?

Blueprint Medicines (BPMC) is presenting at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.

How can investors access Blueprint Medicines' (BPMC) presentations at the upcoming conferences?

Investors can access live webcasts of Blueprint Medicines' (BPMC) presentations through the Investors & Media section of the company's website at http://ir.blueprintmedicines.com.

How long will replays of Blueprint Medicines' (BPMC) conference presentations be available?

Replays of Blueprint Medicines' (BPMC) conference presentations will be archived on the company's website for 30 days following each presentation.

Blueprint Medicines Corporation

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

5.92B
62.85M
0.9%
104.77%
6.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE